VIRVir Biotechnology, Inc.

$1B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$66M+76957.0% YoY

Gross Profit

$66M100.0% margin

Operating Income

-$29M-43.8% margin

Net Income

-$31M-47.0% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+1059.0%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$672M

Total Liabilities

$108M

Stockholders' Equity

$564M

Cash & Equivalents

$372M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66M	$86,000	+76957.0%
Gross Profit	$66M	-$30M	+323.0%
Operating Income	-$29M	-$36M	+18.8%
Net Income	-$31M	-$34M	+8.1%

Revenue Segments

License

$23M100%

VIR Q2 2020 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena